Safety precautions list for taking Mavakatai/Mafantuo

As a drug for the treatment of obstructive hypertrophic cardiomyopathy (HCM), mavacamten has demonstrated significant efficacy in clinical applications. However, patients still need to be aware of some potential risks when using this drug, especially in terms of heart failure, drug interactions, embryo-fetal toxicity, etc. Understanding these safety precautions and following your doctor's instructions can help patients use this drug more safely.

1. Heart Failure Risk

The main function of Mavaceta is to reduce cardiac contractile function, thereby alleviating the symptoms of HCMHCM. However, this effect may also cause heart failure or worsen existing heart failure. The risk of heart failure is higher in people who have abnormal heart rhythms or serious complications such as infections. Therefore, during treatment, the patient's cardiac function, especially left ventricular ejection fraction (LVEF), needs to be monitored regularly. If the LVEF is less than 55%, Mavaceta is not recommended.

During treatment, any new symptoms such as chest pain, dyspnea, or fatigue may be symptoms of heart failure and require timely evaluation of cardiac function.

2. Drug interactions

Mavaceta is mainly metabolized by CYP2C19 and CYP3A4 and may interact with other drugs and increase the risk of heart failure. Therefore, patients should inform their doctor about all medications used, including over-the-counter and herbal medicines, before treatment. Especially when used in combination with omeprazole, cimetidine and other drugs, it may affect the metabolism of Marvaceta and lead to changes in drug efficacy.

3. Embryo-fetal toxicity

Animal studies indicate that mavacate may cause fetal toxicity. Therefore, female patients should confirm that they are not pregnant before treatment and use effective contraceptive measures during treatment. Mavakate may reduce the effectiveness of certain hormonal contraceptives, so additional use of a non-hormonal contraceptive method is recommended.

Mavakate has good efficacy in the treatment ofHCM, but it also comes with certain risks. Patients should follow doctor's advice during use, regularly monitor cardiac function, avoid drug interactions, and strictly adhere to REMS plans and contraceptive measures. Through these safety measures, the risk of potential adverse reactions can be reduced and the safe use of drugs can be ensured.

References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b